Table 1. Clinical and molecular characteristics of patient samples.
| Sample ID | Gender | Age at DX | IgVH | % ZAP 70 | FISH | First Treatment (Rx) Type |
| CLL001 | M | 44 | 93 | 0.4 | Not available | HDMP+Rituxan |
| CLL003 | F | 53 | 92.6 | 0.6 | Not available | FR (2cycles) - good response |
| CLL004 | M | 53 | 100 | 92.5 | 11qdel(16%) | HDMP Rituxan Frontline (3 cycles) |
| CLL005 | M | 65 | 98.6 | 43.6 | tri12 (90%) | Leukeran (4 mg/day) |
| CLL006 | F | 61 | 99.6 | 45.2 | normal FISH | F; then FR (4 cyc) - MRD on BM |
| CLL007 | M | 66 | 99.3 | 79.1 | tri 12 (84%) | Leukeran |
| CLL008 | M | 72 | 95.8 | 3 | 13q del (73%) | Leukeran |
| CLL009 | M | 81 | 95.2 | 9.8 | 13q del (100%) | Chloroambucil |
| CLL010 | M | 48 | 89 | 5 | Not available | Fludarabine (3 cycles) |
| CLL011 | M | 57 | 93.3 | 1.1 | tri 12(75%) | ASCENTA-002 |
| CLL012 | F | 72 | 96.8 | 1.2 | Not available | no Rx |
| CLL013 | M | 59 | 99.6 | 62.8 | tri 12(89%) | Chlorambucil |
| CLL014 | M | 54 | 90.5 | 0.5 | tri 12 (karyotype) | High dose chemoRx w/BM transplant |
| CLL015 | F | 51 | 100 | 91.9 | tri 12 (82%) | ASCENTA-002 |
| CLL016 | F | 53 | 93 | 0.1 | Normal FISH | HDMP+R 04 Frontline |
| CLL017 | F | 39 | 96.1 | 10.1 | Normal Karyotype | no Rx |
| CLL018 | M | 55 | 100 | 91.1 | 13qdel(70%) | HDMP+R 04 (3 cycles) Frontline |
| CLL019 | M | 50 | 100 | 45.9 | Normal FISH | Rituximab (3 cycles) - 4 weeks |
| CLL020 | M | 43 | 91.9 | 1.1 | 13 del (99%) | Chlorambucil |
| CLL021 | M | 66 | 100 | 65.3 | 13 del (99%) | Solumedrol Rituxan |
| CLL022 | M | 48 | 100 | 73.1 | tri 12 (80%) | no Rx |
| CLL023 | M | 72 | 94.7 | 1.3 | 13 del (17%) | GMCSF and Rituxan |
| CLL024 | F | 49 | 100 | 51.8 | Not available | no Rx |
IgVH mutational status and percent ZAP70-positive cells determined as previously described [62].